Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 8.44
(1.56%)
SEK 8.44
(1.56%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 496.24 Million SEK | 46.82% |
| 2022 | 338 Million SEK | -25.08% |
| 2021 | 451.16 Million SEK | 10.98% |
| 2020 | 406.51 Million SEK | 19.17% |
| 2019 | 341.1 Million SEK | 13.1% |
| 2018 | 301.6 Million SEK | 152.33% |
| 2017 | 119.52 Million SEK | 46.39% |
| 2016 | 81.65 Million SEK | -8.49% |
| 2015 | 89.22 Million SEK | 50.29% |
| 2014 | 59.36 Million SEK | 16.45% |
| 2013 | 50.98 Million SEK | 132878.58% |
| 2012 | 38.33 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 540.66 Million SEK | 8.95% |
| 2024 Q2 | 478.73 Million SEK | -11.45% |
| 2023 FY | 496.24 Million SEK | 46.82% |
| 2023 Q4 | 496.24 Million SEK | -18.99% |
| 2023 Q1 | 264.54 Million SEK | -21.73% |
| 2023 Q2 | 340.07 Million SEK | 28.55% |
| 2023 Q3 | 612.55 Million SEK | 80.12% |
| 2022 Q4 | 338 Million SEK | 35.1% |
| 2022 Q3 | 250.18 Million SEK | -22.18% |
| 2022 Q2 | 321.49 Million SEK | -14.89% |
| 2022 Q1 | 377.74 Million SEK | -16.27% |
| 2022 FY | 338 Million SEK | -25.08% |
| 2021 Q3 | 528.99 Million SEK | -14.39% |
| 2021 FY | 451.16 Million SEK | 10.98% |
| 2021 Q1 | 673.62 Million SEK | 65.71% |
| 2021 Q2 | 617.9 Million SEK | -8.27% |
| 2021 Q4 | 451.16 Million SEK | -14.71% |
| 2020 Q4 | 406.51 Million SEK | -7.62% |
| 2020 Q3 | 440.04 Million SEK | 51.13% |
| 2020 Q1 | 313.86 Million SEK | -7.99% |
| 2020 FY | 406.51 Million SEK | 19.17% |
| 2020 Q2 | 291.16 Million SEK | -7.23% |
| 2019 Q2 | 268.75 Million SEK | -8.32% |
| 2019 FY | 341.1 Million SEK | 13.1% |
| 2019 Q1 | 293.14 Million SEK | -2.81% |
| 2019 Q4 | 341.1 Million SEK | 37.29% |
| 2019 Q3 | 248.46 Million SEK | -7.55% |
| 2018 Q2 | 143.65 Million SEK | 15.72% |
| 2018 FY | 301.6 Million SEK | 152.33% |
| 2018 Q3 | 172.11 Million SEK | 19.81% |
| 2018 Q1 | 124.13 Million SEK | 3.86% |
| 2018 Q4 | 301.6 Million SEK | 75.23% |
| 2017 Q2 | 124.93 Million SEK | 15.71% |
| 2017 Q4 | 119.52 Million SEK | -3.16% |
| 2017 FY | 119.52 Million SEK | 46.39% |
| 2017 Q3 | 123.43 Million SEK | -1.2% |
| 2017 Q1 | 107.97 Million SEK | 32.24% |
| 2016 FY | 81.65 Million SEK | -8.49% |
| 2016 Q2 | 82.33 Million SEK | -3.02% |
| 2016 Q1 | 84.89 Million SEK | -4.85% |
| 2016 Q4 | 81.65 Million SEK | -0.34% |
| 2016 Q3 | 81.92 Million SEK | -0.49% |
| 2015 Q2 | 65.25 Million SEK | 0.0% |
| 2015 FY | 89.22 Million SEK | 50.29% |
| 2015 Q4 | 89.22 Million SEK | 0.0% |
| 2014 Q3 | 47.18 Million SEK | 10.96% |
| 2014 Q4 | 59.36 Million SEK | 25.81% |
| 2014 Q1 | 42.52 Million SEK | -16.58% |
| 2014 Q2 | 42.52 Million SEK | 0.0% |
| 2014 FY | 59.36 Million SEK | 16.45% |
| 2013 Q4 | 50.98 Million SEK | 37.68% |
| 2013 Q3 | 37.02 Million SEK | 0.0% |
| 2013 FY | 50.98 Million SEK | 132878.58% |
| 2013 Q1 | - SEK | -100.0% |
| 2012 Q4 | 38.33 Thousand SEK | 0.0% |
| 2012 FY | 38.33 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Active Biotech AB (publ) | 44 Million SEK | -1027.836% |
| Biovica International AB (publ) | 131.4 Million SEK | -277.639% |
| Cantargia AB (publ) | 223.71 Million SEK | -121.824% |
| CombiGene AB (publ) | 120.61 Million SEK | -311.442% |
| Cyxone AB (publ) | 43.65 Million SEK | -1036.75% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -1640.732% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -1544.674% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -530.621% |
| Fluicell AB (publ) | 9.34 Million SEK | -5213.148% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -41.247% |
| Mendus AB (publ) | 755.95 Million SEK | 34.355% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -252.958% |
| I-Tech AB | 152.44 Million SEK | -225.53% |
| Intervacc AB (publ) | 259.61 Million SEK | -91.151% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -1376.841% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -78.029% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -2376.164% |
| OncoZenge AB (publ) | 20.34 Million SEK | -2339.764% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -695.562% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 24.064% |
| Lipum AB (publ) | 12.11 Million SEK | -3997.836% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -318.951% |
| Ziccum AB (publ) | 14.97 Million SEK | -3214.507% |
| BioArctic AB (publ) | 1.18 Billion SEK | 58.161% |
| Genovis AB (publ.) | 288.85 Million SEK | -71.797% |
| Camurus AB (publ) | 1.9 Billion SEK | 73.989% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -180.175% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -698.443% |
| Aptahem AB (publ) | 63.02 Million SEK | -687.384% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 35.153% |
| Kancera AB (publ) | 65.64 Million SEK | -655.98% |
| Saniona AB (publ) | 64.14 Million SEK | -673.659% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -836.582% |
| AcouSort AB (publ) | 34.51 Million SEK | -1337.858% |
| Xintela AB (publ) | 18.39 Million SEK | -2597.733% |
| Abliva AB (publ) | 87.49 Million SEK | -467.147% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 60.565% |
| Amniotics AB (publ) | 26.08 Million SEK | -1802.354% |
| 2cureX AB (publ) | 16.62 Million SEK | -2884.95% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -8066.003% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 73.889% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 51.255% |
| Biosergen AB | 7.2 Million SEK | -6791.376% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -1082.697% |
| Corline Biomedical AB | 100.1 Million SEK | -395.727% |
| NextCell Pharma AB | 81.28 Million SEK | -510.481% |
| Nanologica AB (publ) | 77.42 Million SEK | -540.907% |
| LIDDS AB (publ) | 17.65 Million SEK | -2710.807% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 34.721% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 64.558% |
| SynAct Pharma AB | 228.01 Million SEK | -117.634% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -1754.232% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -2186.554% |
| Alzinova AB (publ) | 123.18 Million SEK | -302.835% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -469.928% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -108.177% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -5769.284% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -482.266% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -3237.467% |
| Simris Alg AB (publ) | 174.55 Million SEK | -184.298% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -128.646% |